209 related articles for article (PubMed ID: 37468280)
1. Current progress in genomics and targeted therapies for neurofibromatosis type 2.
Hiruta R; Saito K; Bakhit M; Fujii M
Fukushima J Med Sci; 2023 Aug; 69(2):95-103. PubMed ID: 37468280
[TBL] [Abstract][Full Text] [Related]
2. Targeted deep sequencing of DNA from multiple tissue types improves the diagnostic rate and reveals a highly diverse phenotype of mosaic neurofibromatosis type 2.
Teranishi Y; Miyawaki S; Hongo H; Dofuku S; Okano A; Takayanagi S; Ota T; Yoshimura J; Qu W; Mitsui J; Nakatomi H; Morishita S; Tsuji S; Saito N
J Med Genet; 2021 Oct; 58(10):701-711. PubMed ID: 33067351
[TBL] [Abstract][Full Text] [Related]
3. [Current Topics on Precision Medicine for Neurofibromatosis Type 2].
Hiruta R; Fujii M
No Shinkei Geka; 2022 Jan; 50(1):150-161. PubMed ID: 35169095
[TBL] [Abstract][Full Text] [Related]
4. Origins of biallelic inactivation of NF2 in neurofibromatosis type 2.
Xue L; He W; Zhang Y; Wang Z; Chen H; Chen Z; Zhu W; Liu D; Jia H; Jiang Y; Wang Z; Wu H
Neuro Oncol; 2022 Jun; 24(6):903-913. PubMed ID: 34918118
[TBL] [Abstract][Full Text] [Related]
5. Application of COLD-PCR for improved detection of NF2 mosaic mutations.
Paganini I; Mancini I; Baroncelli M; Arena G; Gensini F; Papi L; Sestini R
J Mol Diagn; 2014 Jul; 16(4):393-9. PubMed ID: 24815379
[TBL] [Abstract][Full Text] [Related]
6. Neurofibromatosis type 2 (NF2): diagnosis and management.
Lloyd SK; Evans DG
Handb Clin Neurol; 2013; 115():957-67. PubMed ID: 23931824
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms.
Ruggieri M; Praticò AD; Evans DG
Semin Pediatr Neurol; 2015 Dec; 22(4):240-58. PubMed ID: 26706012
[TBL] [Abstract][Full Text] [Related]
8. Neurofibromatosis type 2.
Asthagiri AR; Parry DM; Butman JA; Kim HJ; Tsilou ET; Zhuang Z; Lonser RR
Lancet; 2009 Jun; 373(9679):1974-86. PubMed ID: 19476995
[TBL] [Abstract][Full Text] [Related]
9. Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.
Ruggieri M; Praticò AD; Serra A; Maiolino L; Cocuzza S; Di Mauro P; Licciardello L; Milone P; Privitera G; Belfiore G; Di Pietro M; Di Raimondo F; Romano A; Chiarenza A; Muglia M; Polizzi A; Evans DG
Acta Otorhinolaryngol Ital; 2016 Oct; 36(5):345-367. PubMed ID: 27958595
[TBL] [Abstract][Full Text] [Related]
10. The genetic landscape and possible therapeutics of neurofibromatosis type 2.
Ghalavand MA; Asghari A; Farhadi M; Taghizadeh-Hesary F; Garshasbi M; Falah M
Cancer Cell Int; 2023 May; 23(1):99. PubMed ID: 37217995
[TBL] [Abstract][Full Text] [Related]
11. In vitro antisense therapeutics for a deep intronic mutation causing Neurofibromatosis type 2.
Castellanos E; Rosas I; Solanes A; Bielsa I; Lázaro C; Carrato C; Hostalot C; Prades P; Roca-Ribas F; Blanco I; Serra E;
Eur J Hum Genet; 2013 Jul; 21(7):769-73. PubMed ID: 23188051
[TBL] [Abstract][Full Text] [Related]
12. Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.
Louvrier C; Pasmant E; Briand-Suleau A; Cohen J; Nitschké P; Nectoux J; Orhant L; Zordan C; Goizet C; Goutagny S; Lallemand D; Vidaud M; Vidaud D; Kalamarides M; Parfait B
Neuro Oncol; 2018 Jun; 20(7):917-929. PubMed ID: 29409008
[TBL] [Abstract][Full Text] [Related]
13. Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function.
Yang C; Asthagiri AR; Iyer RR; Lu J; Xu DS; Ksendzovsky A; Brady RO; Zhuang Z; Lonser RR
Proc Natl Acad Sci U S A; 2011 Mar; 108(12):4980-5. PubMed ID: 21383154
[TBL] [Abstract][Full Text] [Related]
14. NF2: the wizardry of merlin.
Xiao GH; Chernoff J; Testa JR
Genes Chromosomes Cancer; 2003 Dec; 38(4):389-99. PubMed ID: 14566860
[TBL] [Abstract][Full Text] [Related]
15. The genetic and molecular pathogenesis of NF1 and NF2.
Yohay KH
Semin Pediatr Neurol; 2006 Mar; 13(1):21-6. PubMed ID: 16818172
[TBL] [Abstract][Full Text] [Related]
16. Incidence of mosaicism in 1055 de novo NF2 cases: much higher than previous estimates with high utility of next-generation sequencing.
Evans DG; Hartley CL; Smith PT; King AT; Bowers NL; Tobi S; Wallace AJ; Perry M; Anup R; Lloyd SKW; Rutherford SA; Hammerbeck-Ward C; Pathmanaban ON; Stapleton E; Freeman SR; Kellett M; Halliday D; Parry A; Gair JJ; Axon P; Laitt R; Thomas O; Afridi SK; Obholzer R; ; Duff C; Stivaros SM; Vassallo G; Harkness EF; Smith MJ
Genet Med; 2020 Jan; 22(1):53-59. PubMed ID: 31273341
[TBL] [Abstract][Full Text] [Related]
17. NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations.
Schroeder RD; Angelo LS; Kurzrock R
Oncotarget; 2014 Jan; 5(1):67-77. PubMed ID: 24393766
[TBL] [Abstract][Full Text] [Related]
18. Sustained response to bevacizumab in a patient with mosaic neurofibromatosis type 2 carrying the
Basenach E; Förster A; Raab P; Alzein S; Schmidt G; Krauss JK; Schlegelberger B; Heidenreich F; Auber B; Hartmann C; Wiese B; Weber RG
Clin Neuropathol; 2022; 41(4):162-167. PubMed ID: 35445657
[TBL] [Abstract][Full Text] [Related]
19. Loss of the NF2 gene and merlin occur by the tumorlet stage of schwannoma development in neurofibromatosis 2.
Stemmer-Rachamimov AO; Ino Y; Lim ZY; Jacoby LB; MacCollin M; Gusella JF; Ramesh V; Louis DN
J Neuropathol Exp Neurol; 1998 Dec; 57(12):1164-7. PubMed ID: 9862639
[TBL] [Abstract][Full Text] [Related]
20. A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor.
Hirokawa Y; Tikoo A; Huynh J; Utermark T; Hanemann CO; Giovannini M; Xiao GH; Testa JR; Wood J; Maruta H
Cancer J; 2004; 10(1):20-6. PubMed ID: 15000491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
